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Summary 
With the new focus on functional recovery in schizophrenia, factors limiting function in schiz-
ophrenia are receiving increasing attention.
Neurocognitive (NC) impairment accounts for 20-60% of the variance in real-world outcome. 
The effect sizes of the associations between NC and functional outcome tend to be medium 
for specific domains and larger for summary scores. Mapping NC deficits often requires the 
use of extensive test batteries that are lengthy and costly and require advanced training in as-
sessment to score and utilize the results. The currently available NC assessment instruments 
differ widely in the population intended for use, administration time, interpretation of results, 
and the assessment of certain NC domains. 
Social cognition (SC) contributes to functional outcomes beyond the influence of NC and may 
have a greater impact than NC on social outcomes. In addition, SC may mediate the relation-
ship between NC and social functions in both chronic and first-episode patients. The degree 
of the relationship between SC and functioning varies, depending on the SC domain and the 
type of functional outcome assessed. In the past, there has been controversy over what SC 
processes should cover. Moreover, the most critical issue is that there is no consensus in 
the field as to which measures best assess each SC domain. As a result, a heterogeneous 
group of tasks have been administered with significant conceptual overlap and questionable 
psychometric properties across studies. This problem is present across all SC domains and 
contributes to the inconsistency of the reported findings.
The assessment of real-life functioning in schizophrenia presents complex challenges from 
variability in the operational definition of functional outcome to problems in identifying op-
timum information sources. In this context, there are still few satisfactorily reliable instru-
ments for the assessment of functional outcomes that are practical in terms of time involved, 
and most real-life functional outcome scales seem to be largely redundant with each other 
when utilized simultaneously. 
This update describes the main NC and social cognition (SC) batteries and real-world assess-
ments used in schizophrenia and discuss their advantages and disadvantages.
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Introduction
During the last two decades, the field of psychiatry has moved toward the 
goals of remission and recovery rather mere symptom improvement 1. Recov-
ery refers to patients being able to function normally at work or school, in the 
community, and at home. It may occur even if patients are still experiencing 
some ongoing symptoms. Recovery can also involve a host of subjective 
experiences including attaining a self-appraised acceptable quality of life or 
reasonable sense of social rank and recapturing a cohesive sense of oneself 
as a valuable person in the world. Recovery requires that the person diag-
nosed with schizophrenia be an active agent in that process 2. It has been 
suggested that only 13.7% of subjects in their first episode of schizophrenia 
or schizoaffective disorder met full recovery criteria for 2 years or longer 3.
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processing speed, visual learning and memory, verbal 
learning and memory, and social cognition. The seventh 
domain, SC, was included because it was viewed as 
an ecologically important domain of cognitive deficit in 
schizophrenia that shows promise as a mediator of NC 
effects on functional outcome. Some NC domains were 
not included in this list, i.e., verbal comprehension was 
not included in the cognitive battery as it was consid-
ered resistant to change 12.
A growing body of the literature suggests that many of 
these deficits can be traced to a generalized cognitive 
impairment  13. Patients with schizophrenia have been 
shown to perform below the level of their peers by over 
one standard deviation (SD) and have a unique profile 
of impairment of cognitive domains 14.
Thus, the evaluation of a patient with schizophrenia 
should begin with a general assessment to evaluate the 
patient’s average cognitive functioning, investigating 
the school or works performances, any developmental 
delays or change in overall functioning, and the ability 
to solve problems in daily lives. Proverb interpretation 
brings out unusual thought content and deficits in ex-
ecutive function. 
Tests for measuring cognition
Many instruments are available for the assessment of 
cognitive functioning in patients with schizophrenia. 
These instruments differ widely in the population intend-
ed for use, administration time, interpretation of results, 
and the assessment of certain cognitive domains, and 
little guidance is available for selection among these in-
struments for clinical trials. 
Mapping cognitive deficits often requires the use of ex-
tensive test batteries that are lengthy 15 and costly and 
require advanced training in assessment to score and 
utilize the results. In particular, due to the nature of def-
icits in schizophrenia, it is reasonable to suggest the 
need for an affordable, easy to administer test that iden-
tifies deficits in cognitive skills in order to recommend 
an intervention for addressing these deficits.
Useful tests for clinical practice are described below.
Wechsler Adult Intelligence Scale
Abbreviated versions of the Wechsler Adult Intelligence 
Scale (WAIS)  16 have been developed as pragmatic 
timesaving devices that balance the length of assess-
ment with accurate estimates of the overall level of 
general intellectual functioning. Two main types of ab-
breviations of the WAIS have been proposed 17: “select-
subtest” and “select-item”. Selected subtests abbrevia-
tions reduce the amount of time spent on test assess-
ment by only administering selected subtests to obtain 
estimated cognitive functioning scores 18. This selection 
can vary from seven to as few as two subtests, in which, 
A key focus of current research is to identify factors lim-
iting function in schizophrenia. 
Neurocognitive (NC) impairment has long been rec-
ognized as a core component of schizophrenia and is 
closely linked to social and occupational outcome  4. 
This association between NC and outcome is robust – it 
was replicated and extended in many countries, using 
many different types of assessments, in different patient 
groups across phase of illness, including prodromal 5. 
NC impairment accounts for 20-60% of the variance in 
real-world outcome  4 and has been shown to predict 
social outcomes more closely than do psychotic symp-
toms  6. However, effect sizes of the associations be-
tween NC and functional outcome tend to be medium 
for specific domains and larger for summary scores.
Thus, the questions have shifted from whether NC is 
related to outcome to how NC is related to outcome. 
Further, not all types of NC are equally important when it 
comes to navigating the real world. 
In a 1996 review, Green  7 has shown that several NC 
domains were associated with specific functional 
outcomes in schizophrenia. The strongest evidence 
showed that verbal memory was associated with all 
measures of functional outcomes; moreover other cor-
relations were found between vigilance and both social 
problem solving and skill acquisition, and between card 
sorting and community functioning.
This growing realization that NC deficits are central to 
outcomes have directed attention at the assessment of 
these important aspects of the disorders. 
This update describes the main NC and social cogni-
tion (SC) batteries and real-world assessments used in 
schizophrenia and discuss their advantages and disad-
vantages.
Cognitive assessment
NC deficits often precede the manifestation of psycho-
sis and might be the first signs of schizophrenia in at-
risk patients 8, they are orthogonal to positive and nega-
tive symptoms 9, are relatively stable over time, continue 
to be present after remission of psychosis, and are rela-
tively unaffected by antipsychotic treatment 10. 
Moreover, although NC assessment does not represent 
a clear diagnostic marker, as a clear profile on neuro-
psychological tests has not been defined, it can offer an 
understanding of NC deficits and guide treatment tar-
gets and recommendations. Several investigators have 
emphasized different area of cognition. The Measure-
ment and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative 11, sponsored by the 
United States National Institute of Mental Health (NIMH), 
identified seven distinct, separable cognitive domains 
as commonly deficient in schizophrenia: attention/vigi-
lance, working memory, reasoning and problem solving, 
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from academia, government, and the pharmaceutical 
industry led to agreement on seven cognitive domains 
for the battery and on five criteria for test selection. The 
criteria emphasized characteristics required for cogni-
tive measures in the context of clinical trials: test-retest 
reliability; utility as a repeated measure; relationship to 
functional status; potential changeability in response to 
pharmacological agents; and practicality for clinical tri-
als and tolerability for patients. Cognitive function was 
measured according to the 7 cognitive domains of the 
MCCB derived from scores on 10 cognitive measures: 
speed of processing (Trail Making Test Part A; Brief 
Assessment of Cognition in Schizophrenia: Symbol 
coding; Category fluency test, animal naming), atten-
tion/vigilance (Continuous Performance Test: Identical 
Pairs), working memory (Wechsler Memory Scale, spa-
tial span subset; Letter Number Span test), verbal learn-
ing (refers to immediate verbal memory, Hopkins Verbal 
Learning Test (HVLT)-Revised, immediate recall), visual 
learning (refers to immediate visual memory, Brief Vi-
suospatial Memory Test-Revised), reasoning and prob-
lem solving (Neuropsychological Assessment Battery 
(NAB), mazes subtest), and social cognition (Mayer-
Salovey-Caruso Emotional Intelligence Test (MSCEIT): 
managing emotions branch). The MCCB can be admin-
istered in 1 to 1.5 hours.
After substantial use in the testing ground of multisite 
clinical trials, the MCCB has demonstrated impressive 
psychometrics. It has shown sensitivity to improvement 
from interventions, most notably for cognitive training 
interventions so far. The MCCB also tracks with key 
biomarkers, which is an important feature as efforts 
are made to apply experimental medicine principles, 
such as target engagement, to psychiatric treatment 
trials. Two limitations of the MCCB should be pointed 
out. First, the MCCB was developed to facilitate drug 
approval from the U.S. FDA. Because clinical trials are 
often international, it soon became obvious that a key 
limitation of the MCCB was that it was available only in 
English. Hence, the MCCB has now been professionally 
translated and is commercially available in over 20 lan-
guages (see www.matricsinc.org for a listing). With the 
help of an industry-academic-government consortium 
(MATRICS-CT), representative normative data were col-
lected in key countries and these norms were used to 
create international scoring programs. Recently, Mucci 
et al. 26 have reported the normative Italian data. A sec-
ond change reflects the growing awareness that NC 
and SC are separable dimensions. It is possible that 
a treatment will affect SC and NC differently, and that 
is assumed for specific interventions, that are focused 
on one area or the other. To allow trial investigators to 
examine NC only, the MCCB scoring program now pro-
vides an option for a “neurocognitive composite” that 
for example, only the subtests Vocabulary and Block 
Design are being administered. Select-item abbrevia-
tions involve the administration of previously selected 
items from all subtests. The Satz-Mogel short form 19 is 
frequently used as a “select-item” abbreviation and has 
shown to be an accurate measure of general intellectual 
ability when compared with the full WAIS 20. In the Satz-
Mogel method, the item selection concerns the admin-
istration of every second (or third) item in WAIS subtests 
(e.g., Information, Block Design) that take a long time to 
administer.
The proposed 15-minute version of the WAIS by Verlt-
horst and colleagues 21, that includes only select items 
from three subtests, may serve as a useful screening 
device for general intellectual ability in research or clini-
cal settings, and is recommended when a quick and 
accurate IQ estimate is desired.
Repeatable Battery for the Assessment of 
Neuropsychological status 
The Repeatable Battery for the Assessment of Neuro-
psychological status (RBANS) is a standardized screen-
ing instrument designed to assess global neuropsy-
chological functioning in a brief administration. Several 
studies have supported the psychometric properties of 
the RBANS 22, with past research reporting acceptable 
test-retest reliability, internal consistency, and concur-
rent validity 23. The RBANS has been found to be a valid 
measure of the cognitive decline associated with various 
neurological conditions including stroke, Alzheimer’s 
disease, multiple sclerosis, Parkinson’s disease, and 
Huntington’s disease. This instrument measures several 
cognitive domains of interest in schizophrenia – imme-
diate memory, visuospatial/constructional ability, lan-
guage, attention, and delayed memory – and provides 
a global measure, the total scale score. In addition, the 
RBANS offers two alternate forms to reduce the poten-
tial influence of practice effects in serial test adminis-
tration. Wilk and colleagues  24 found that RBANS was 
reliable and sensitive enough to differentiate between 
patients with schizophrenia and healthy subjects and 
was suited for repeated measures.
Measurement and Treatment Research to Improve 
Cognition in Schizophrenia Consensus Cognitive Battery
The Measurement and Treatment Research to Improve 
Cognition in Schizophrenia (MATRICS) Consensus 
Cognitive Battery (MCCB) 25 was designed by the NIMH 
to support the development of pharmacological agents 
for improving the neurocognitive impairments in schizo-
phrenia. It has been recommended by the United States 
Food and Drug Administration (FDA) to assess cogni-
tive impairment as the primary outcome measure in reg-
istry trials of schizophrenia 25. An initial MATRICS con-
sensus conference involving more than 130 scientists 
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gists. Third, the battery had assess aspects of each 
of the cognitive domains known to be impaired in pa-
tients with schizophrenia, including executive functions, 
memory, attention, and processing speed. Fourth, the 
tests selected had to have been found to be sensitive to 
improvements with atypical antipsychotics. Finally, the 
tests had to have been found to be related to measures 
of functional outcome in schizophrenia patients.
Schizophrenia Cognition Rating Scale
The Schizophrenia Cognition Rating Scale (SCoRS) 28 as-
sesses the following cognitive domains: memory, work-
ing memory, attention, reasoning and problem solving, 
language and motor skills. The SCoRS has several ad-
vantages including brief administration time, approxi-
mately 15  min per interview, association to real-world 
functioning, good test-retest reliability, and correlations 
with performance-based measures of cognition 28. More-
over, its rating is based on information from three sepa-
rate sources including patient, informant of the patient 
who has regular contact with patient and interviewer.
The SCoRS has shown good reliability, validity, and sen-
sitivity to cognitive impairment in schizophrenia, with the 
advantage of brief administration and scoring time. The 
SCoRS was developed to measure cognitive functions 
through questions about cognitions related to daily life 
events 28. It consists of 20 items. Each item is rated on 
a scale ranging from 1 to 4 with higher scores reflecting 
a greater degree of impairment. Every item is given an-
chor points based on the degree of their daily problems. 
Two studies have demonstrated significant correlations 
between SCoRS ratings with NC functions as well as 
psychosocial functioning, in Singaporean, and Italian 
schizophrenia patients 29 30. 
Social cognition assessment
SC impairments may precede onset of the schizophre-
nia 31-33 and are present early in the illness 34. Such SC 
deficits have been consistently linked to a variety of 
real-world outcomes, such as social competence, com-
munity functioning, and quality of life  35. The extent of 
overlap between SC and NC has been an area of de-
bate within the literature. SC contributes to functional 
outcomes beyond the influence of NC and may have 
a greater impact than NC on social outcomes  36-38. In 
addition, SC may mediate the relationship between NC 
and social functions in both chronic  39-41 and first-epi-
sode patients 42. Moreover, treating SC deficits leads to 
improvements in real-world social outcomes, including 
social adjustment, social functioning, social relation-
ships, aggressive incidents, and social skills 43.
The degree of the relationship between SC and func-
tioning varies, depending on the SC domain and the 
type of functional outcome assessed. 
does not include SC. A limitation of the MCCB is that it 
does not have an option for a SC composite, because 
there is only one test in that domain.
Brief Assessment of Cognition in Schizophrenia
The Brief Assessment of Cognition in Schizophrenia 
(BACS) 27 is a portable pen-and-paper, concise tool de-
signed to evaluate five different domains of cognitive 
function with six tests (impairment of verbal memory, 
working memory, motor speed, verbal fluency, atten-
tion and processing speed, and executive function), 
assessing the aspects of cognition found to be most 
impaired and most strongly correlated with outcome in 
patients with schizophrenia. 
The BACS is easily performed in clinical settings and 
can be administered by medical professionals in 30-
35  minutes. It yields a high completion rate in these 
patients, and has high reliability. The BACS was found 
to be as sensitive to cognitive impairment in patients 
with schizophrenia as a standard battery of tests that 
required over 2 h to administer. 
The way used to create the BACS and the RBANS was to 
create a new group of tests that assess all or many of the 
key domains of neuropsychological functioning in less 
time than the comprehensive batteries traditionally used. 
With this approach, one can create tests that are spe-
cifically sensitive to the deficits in schizophrenia patients 
and likely to be amenable to change with atypical anti-
psychotics. Assessment batteries such as these require 
the collection of large amounts of data to establish popu-
lation norms, reliability, and validity. These psychometric 
properties make the BACS a promising tool for assessing 
cognition repeatedly in patients with schizophrenia, es-
pecially in clinical trials of cognitive enhancement.
Brief cognitive assessment
The Brief cognitive assessment (BCA) consists of three 
standard tests selected from among those commonly 
included in comprehensive cognitive batteries admin-
istered to patients with schizophrenia: Verbal Fluency 
(letters and categories), Trails A and B, and the Hopkins 
Verbal Learning Test. 
The way used to create the BCA was to select a small 
number of standardized tests widely used in clinical 
neuropsychology, that examine a variety of cognitive 
domains in a very limited fashion. With this approach, 
normative data and information regarding the sensitiv-
ity, reliability and validity of the individual tests included 
in the battery are already available. 
The creation of the BCA was guided by several prin-
ciples. First, the battery had to be very brief (maximum 
15 min), including time for set-up, administration, and 
scoring. Second, tests in the BCA had to be easy to 
administer and score and the results had to be under-
standable to clinicians who were not neuropsycholo-
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the regulation of emotions in oneself and in one’s rela-
tionships with others by presenting vignettes of various 
situations, along with ways to cope with the emotions 
depicted in these vignettes. It was integrated by the 
Facial Emotion Identification Test (FEIT) 47, which exam-
ines emotion perception, and The Awareness of Social 
Inference Test (TASIT) 48, which is a TOM test consisting 
of 7 scales (positive emotions, negative emotions, sin-
cere, simple sarcasm, paradoxical sarcasm, sarcasm 
enriched, lie), organized into three sections: Emotion 
recognition; Social Inference (minimal); Social Inference 
(enriched). The manual of the TASIT was translated into 
Italian by a psychiatrist of the Department of Psychia-
try of the University of Naples SUN. The videotaped vi-
gnettes of the TASIT were dubbed in Italian at the Fono 
Roma Studios (www.fonoroma.com). As to the FEIT, the 
adaptation of the Italian version required the transla-
tions of the six emotions reported on the screen above 
the stimuli.
Real-world functioning assessment 
The assessment of real-life functioning presents com-
plex challenges from variability in the operational defi-
nition of functional outcome to problems in identifying 
optimum information sources 49. Indeed, many different 
strategies have been proposed to assess real-life func-
tioning, including self-report interviews, proxy reports, 
informant interviews  49, direct observations by trained 
clinicians 50, and performance-based measures, which 
assess functional capacity (“what a person is able to 
do under optimal conditions”)  51. However, reports of 
real-life outcomes vary across informants and contain 
elements of error or shortcomings 49. It has been sug-
gested that self-reports should be accepted at face val-
ue even if they reflect patients’ delusional beliefs 52 and 
have limitations such as inaccurate estimations 53. Oth-
er investigators have highlighted the potential for psy-
chotic symptoms, mood states, disorganized thinking, 
lack of insight, and NC deficits to limit the usefulness 
of the self-report methodology in severely ill schizo-
phrenia patients. Furthermore, it has been suggested 
that these measures may not adequately reflect the ef-
fects of various interventions 54. However, studies have 
shown that patient self-reports of everyday functioning 
in schizophrenia often do not converge with objective 
evidence or the reports of others  55  56. Self-reports of 
functioning therefore appear problematic, and alterna-
tive assessment methods may be required. However, 
many patients have no caregivers to provide informa-
tion, and variance in their reports can be influenced 
by the amount of contact with the subject and situation 
specificity of the observation. High contact clinicians 
appear to generate ratings of everyday functioning 
that are more closely linked to patients’ ability scores 
Even if the study of SC is quite robust, its study is in 
some ways less developed than that of NC. In the past, 
there has been controversy over what SC processes 
should cover. 
Moreover, the most critical issue is that there is no con-
sensus in the field as to which measures best assess 
each SC domain. As a result, a heterogeneous group of 
tasks have been administered with significant concep-
tual overlap and questionable psychometric properties 
across studies. This problem is present across all SC 
domains and contributes to the inconsistency of the re-
ported findings 44.
The Social Cognition Psychometric Evaluation 
(SCOPE) 45 study was designed to address these chal-
lenges: first, to achieve a consensus on the crucial SC 
domains in schizophrenia; second, to evaluate the psy-
chometric properties of existing measures and their 
suitability for clinical trials.
Using methods similar to other NIMH measurement 
initiatives (eg, MATRICS, MATRICS-CT, and VALERO), 
the panel of experts in the schizophrenia-spectrum re-
search field identified and supported the value of four 
key domains, including emotion processing (EP; the 
ability to perceive and appropriately use emotions), 
theory of mind (ToM; the ability to infer ones own and 
others’ mental states), social perception (SP; ability to 
decode and interpret social cues in others), and attri-
butional style (AS; ability to explain the causes or make 
sense of social interactions and events). Two additional 
domains, social metacognition and social reciproc-
ity, however suggest avenues for expansion of SC re-
search.
Using RAND consensus ratings, the expert survey of 
SC produced 108  different outcomes measures, with 
many of these domains and measures being very close-
ly related to each other. The panelists lastly selected the 
following measures for further evaluation: Ambiguous 
Intentions Hostility Questionnaire, Bell Lysaker Emotion 
Recognition Task, Penn Emotion Recognition Test, Re-
lationships Across Domains, Reading the Mind in the 
Eyes Test, The Awareness of Social Inferences Test, 
Hinting Task, and Trustworthiness Task. However, the 
similarity of many of these measures to each other has 
led to challenges in direct comparisons of their useful-
ness, as many of these assessments have overlapping 
content. Moreover, only a limited amount of psychomet-
ric information is currently available for the candidate 
measures, which underscores the need for well-validat-
ed and standardized measures in this area. 
In the context of a multicenter study of the Italian Net-
work for Research on Psychoses (NIRP), the assess-
ment of SC included a test contained in the MCCB: the 
Mayer-Salovey-Caruso Emotional Intelligence Test (MS-
CEIT)  46, managing emotion section, which examines 
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est (social functioning, everyday living skills, or both 
these areas -”hybrid” scales). Scales were rated on a 
9-point (1-9) scale, where scores of 1-3 were poor, 4-6 
were fair to good and 7-9 were very good to superb. 
The two scales that scored highest across the various 
criteria for each of the classes of scales (hybrid, social 
functioning, and everyday living skills) were selected 
for use in the first substudy of VALERO 49. The scales 
selected were the Quality-of-Life Scale, Specific Levels 
of Functioning Scale, Social Behavior Schedule, Social 
Functioning Scale, Independent Living Skills Sched-
ule, and Life Skills Profile. The overall results of this first 
substudy of VALERO show that all examined scales 
can be considered as somewhat useful in their current 
versions. Moreover, many of these scales lack critical 
data regarding reliability across investigators and rela-
tionship with neuropsychiatric and functional capacity 
performance. Ratings for usefulness across multiple 
raters were also quite low, partly because many of these 
scales do not have alternate forms that attempt to cap-
ture the differing perspectives of different raters. As an 
entirely effective measure of the real-life outcomes com-
ponent of the functional outcomes construct has not yet 
been identified, some measures are likely to be suitable 
in the interim. Thus, comprehensive real-life function-
ing assessment, using self-report, informant report and 
interviewer best judgment across six different real-life 
functioning rating scales may be required to capture the 
complexity of functional outcome in schizophrenia 58. 
The Specific Levels of Functioning (SLOF) Scale  62 is 
a 43-item multidimensional behavioral survey adminis-
tered in person to the caseworker or caregiver, select-
ed on the basis of his/her familiarity with that person 
or a patient-administered scale completed with verbal 
instructions from the examiner to rate its own perfor-
mance. The scale does not include items relevant to 
psychiatric symptomatology or cognitive dysfunctions, 
but assesses the patient’s current functioning and ob-
servable behavior, as opposed to inferred mental or 
emotional states, and focuses on a person’s skills, as-
sets, and abilities rather than deficits that once served 
as the central paradigm guiding assessment and in-
tervention for persons with disabilities. It comprises six 
subscales: (1) physical functioning, (2) personal care 
skills, (3) interpersonal relationships, (4) social accept-
ability, (5) activities of community living and (6) work 
skills. The work skills domain comprises behaviors im-
portant for vocational performance, but is not a rating 
of behavior during employment. The latter would not be 
feasible, since the majority of patients with schizophre-
nia are unemployed; therefore, the proxy measure of 
work skills from the SLOF is used. Lastly, the SLOF also 
includes an open-ended question asking the informant 
if there are any other areas of functioning not covered 
than friends or relative informants  57. Both types of di-
rect assessment (direct observation versus analogue 
assessment) have advantages and limitations. Real-life 
observations are necessarily individualized and non-
standardized as well as costly and potentially reactive 
(presence of an observer may alter the environment and 
resulting behaviors). To this end, performance-based 
measures of functional capacity have been developed. 
However, they are valid to the extent that they measure 
the relevant skills accurately, but other factors may in-
fluence real-life outcomes, such as financial resources, 
motivation and symptoms of the illness may limit the 
extent to which skills that are present in the behavioral 
repertoire are actually performed in real-life settings 58. 
Overview of everyday real-life outcomes 
In this context, research efforts are increasingly turning 
to the design, evaluation and improvement of relatively 
economical real-life measurement  59-61. Moreover, giv-
en concerns about length and ease of administration, 
as well as burden to the subject for assessment bat-
teries, a practical measure must be both cost efficient 
and require a modest amount of time to administer  59. 
However, there are still few satisfactorily reliable instru-
ments for the assessment of functional outcomes that 
are practical in terms of time involved, and most real-life 
functional outcome scales seem to be largely redun-
dant with each other when utilized simultaneously. One 
upshot of this situation is the Validation of Everyday Re-
al-World Outcomes in schizophrenia (VALERO Expert 
panel) initiative. The goal of this initiative was to iden-
tify the functional rating scale or scales (or subscales 
from existing scales) (self-report and informant-based 
reports) most strongly related to performance-based 
measures of cognition and everyday living skills through 
a comprehensive evaluation of existing instruments 49. 
The outcomes may include social, vocational, indepen-
dent living, self-care or any combination of these. The 
scale characteristics, which were rated by the panel-
ists and were similar to those deemed important in the 
MATRICS process, were: reliability (test-retest and inter-
rater), convergence with performance-based measures 
of functional capacity and neurocognitive performance, 
sensitivity to treatment effects, usefulness for multiple 
informants (e.g., self, friend or relative, case manager, 
or prescriber), relationships with symptom measures, 
practicality and tolerability for people with low educa-
tion levels, and convergence with other measures of 
real-life functional outcomes (including either other 
rating scales or achievement milestones). Among the 
59 measures nominated, the investigators selected the 
11 scales that were the most highly nominated, had the 
most published validity data regarding their psychomet-
ric qualities and best represented the domains of inter-
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share their ratings, discuss discrepancies and negoti-
ate a mutually acceptable set of functionally oriented 
goals for the plan. This process also could serve as a 
form of quality assurance, allowing patients and staff 
to obtain potentially valuable feedback about the pa-
tients’ self-perceptions and help staff to gauge better 
the accuracy of their judgments 62. Lastly, the SLOF has 
direct applications in research on patient outcome and 
program evaluation. 
The SLOF was found to be a reliable and valid scale, with a 
good construct validity and internal consistency, as well as 
a stable factor structure. In the context of the NIRP, the in-
strument was translated in Italian 63 and its construct valid-
ity, internal consistency and factor structure as explored 64.
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by the instrument that may be important in assessing 
functioning in this patient. Each of the questions in 
the above domains is rated on a 5-point Likert scale. 
Scores on the instrument range from 43 to 215. The 
higher the total score, the better the overall functioning 
of the patient. According to the original version of the 
SLOF, the time frame covered by the survey is the past 
week. Each informant is asked to rank how well they 
know the patient on a 5-point Likert scale ranging from 
“not well at all” to “very well.” Ratings on individual items 
of the SLOF may be used to capture the current state 
of overall functioning while showing specific areas of 
therapeutic and rehabilitative need, i.e. to identify goals 
in planning treatment for clients, to develop special in-
tervention or skill-training programs, or to assign clients 
with similar or complementary strengths and needs to 
existing programs. An adaptation of the SLOF is to al-
low patients to rate themselves on each item, while staff 
make independent judgments. Patients and staff then 
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